𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adalimumab in patients with Crohn’s disease – safety and efficacy in an open-label single centre study

✍ Scribed by J. SEIDERER; S. BRAND; J. DAMBACHER; S. PFENNIG; M. JÜRGENS; B. GÖKE; T. OCHSENKÜHN

Book ID
108604885
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
538 KB
Volume
25
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of donepezil over 3
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease
✍ A. Burns; S. Gauthier; C. Perdomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective This 132‐week, open‐label extension study assessed the long‐term efficacy and safety of donepezil in 579 patients with mild to moderate Alzheimer's disease (AD) who had previously participated in a 24‐week double‐blind study of 5 or 10 mg/day donepezil __vs__ placebo. ##

Adalimumab safety in global clinical tri
Adalimumab safety in global clinical trials of patients with Crohn's disease
✍ Jean-Frédéric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr